2. Founded in 2009, Vaxeal, in partnership with leading international research institutes, is
developing therapeutic vaccines in combination with immuno-modulatory drugs for the
treatment of cancers and infectious diseases. Vaxeal’s initial programs have reached the pre-
clinical stage in major disease segments, and are expected to enter into clinical trials in
Europe in 2014 and 2015.
Strong progress has been made in the understanding of the multiple factors limiting
immune response against tumors, and we have developed novel combination strategies
using advanced technologies in order to optimize our vaccines. LSP-based cancer vaccines
as well as advanced delivery systems focus on the optimization of T-cell cross-priming with
the aim of generating a strong T-cell memory response against the tumor. Our combination
with immuno-modulatory drugs addresses known issues related to tumor-mediated
immunosuppression.
Vaxeal is targeting disease segments where high value markets are experiencing rapid
growth and where major unmet patient needs exist.
Our scientists evaluate the best approaches in designing therapeutic vaccine combinations
in order to ensure vaccine safety and efficacy, boost vaccine uptake, determine a safe
dosage range, as well as minimize vaccine-related side effects. Our proprietary technology
platforms allow us to develop relevant and predictive in vitro and in vivo efficacy and safety
assays. They are prerequisites for our first-in-human clinical trials. We are developing an
adapted pharmacovigilance system in order to anticipate potential long-term side effects.
Our ultimate goal is also to improve patient access to new vaccines. The entire Vaxeal
pipeline has been built according to these principles. Survivin, Midkine, Cyclin B1, and HCV
therapeutic vaccines are the first products currently under development.
Vaxeal
Markets
Products
Advantage
Vaxeal’s clinical portfolio is the result of 15 years of research and is unique in
the biopharmaceutical sector. It is protected by numerous patents and is at
the heart of Vaxeal’s anti-cancer therapeutic vaccines platforms. Each
product developed at Vaxeal addresses major unmet medical needs.
Vaxeal is developing game-changing treatments to meet
future healthcare challenges
3. More than ever, patented treatments against unmet medical needs, such as cancer and
infectious diseases, are becoming highly strategic for all biopharmaceutical companies.
These large companies are increasingly relying on external R&D, primarily that of SMEs.
These outsourced research programs now represent as much as 40% of their pipeline.
Vaxeal is forecasting substantial licensing and M&A transactions in the coming years.
By targeting disease segments where high value markets are experiencing rapid growth,
each product developed at Vaxeal has the potential to be a blockbuster with annual sales
exceeding €5 billion. Additionally, these products should qualify for regulatory fast-track
and special protocol assessment.
The innovative Vaxeal cancer vaccines will address a large spectrum of cancer patients, as
they include three tumor antigens (Survivin, Midkine and Cyclin B1), which cover almost all
solid tumors. The clinical results of Phase I/II trials should bring the promise of long-term
survival when administered to cancer patients, and should lead to protective anti-tumor
immunity with limited toxicity and adverse effects. Moreover, a better understanding of the
immunological mechanisms of our vaccines will enable the more efficient development of
vaccines beyond our current indications in the future.
Vaxeal has identified Phase IIa (Clinical Proof of Concept) as being the optimum exit point
from a clinical trial perspective. This development phase, allowing the assessment of human
safety and primary efficacy, offers the best risk-return profile while avoiding the surge in
costs of Phases IIb or III.
Strategy
Exit
Risk
of
failure
Cost
(EUR
Millions)
Milestones
Payment
(EUR
Millions)
Royal8es
Phase
I
85%
1-‐5
5-‐7
<5%
Phase
IIa
35%
3-‐10
50-‐100
10-‐15%
Phase
IIb
25%
50-‐100
300-‐400
High
Phase
III
15%
200-‐300
Very
high
Very
high
Opportunity
Vaxeal focuses on developing therapeutic vaccines to meet
the growing need for improved anti-cancer treatments
4. Vaxeal has also signed an exclusive patent agreement with the Finlay Institute and the University of Cambridge protecting an
advanced new generation of immuno-potentiators. Vaxeal continues to expand, consolidate and update its intellectual
property position.
Vaxeal and the Commissariat à l’Energie Atomique (CEA) have signed an
exclusive worldwide license agreement protecting T cell epitopes of the tumor
antigens Survivin, Midkine, Cyclin B1 and Hepatitis C.
CD4+ Survivin Epitopes and Uses Thereof CEA* 2005
Immunogenic peptides derived from the Midkine protein, as an anticancer vaccine CEA* 2008
Mixture of peptides from Core and NS3 proteins of Hepatitis C virus and applications thereof CEA* 2002
Immunogenic peptides derived from the Cyclin B1 protein, as an anticancer vaccine CEA* 2013
Formulation and composition of survivin-based cancer vaccine Vaxeal 2014
Unique and innovative scientific research is at the heart of
Vaxeal’s value proposition
IP Portfolio
* Exclusive License to Vaxeal
5. Vaxeal Development Pipeline
Products 2013 2014 2015 2016 2017
Survivin (1)
Pre-‐clinical
PoC
studies
Phase
I/II
Phase
IIa
Cyclin B1 (3)
Midkine (2)
Combo (1+2+3)
Industry Highlights: At the end of 2012, the pipeline for therapeutic vaccines had grown to an estimated 400 products and
was larger than that for prophylactic vaccines. The vaccines in development cover more than 70 different conditions but
vaccines for cancer account for over half of the global pipeline (Ernst & Young, Beyond borders: global biotechnology report
2012). Vaxeal is at the forefront of this research with our novel strategy based on optimal combinations of its proprietary
therapeutic vaccines with selected immuno-modulators.
Vaxeal’s optimized cancer vaccines address the issues of the
multiple factors limiting immune response against tumors
Hepatitis C* gen.1-6
* Partnered with China Medical City (CMC)
6. Vaxeal, in partnership with European healthcare stakeholders is an important
contributor to the EU biotechnology sector. Vaxeal’s engagement aims to
foster innovation and promote a favorable business and regulatory
environment for European SMEs.
Synergies between Vaxeal and its partners will improve
patient access to new vaccines
Memberships
Ahmed Bouzidi (Vaxeal Founder & CEO) is a member of the boards of both Vaccines Europe and
European Biopharmaceutical Enterprises (EBE), where he is active in encouraging a more friendly
business and regulatory environment for innovative SMEs.
Vaccines Europe represents major innovative vaccine research companies, which account for a large
share of human vaccines used worldwide. Companies represented within Vaccines Europe are: Abbott
Biologicals, J&J-Crucell, GlaxoSmithKline Vaccines, MedImmune, MSD, Novartis Vaccines, Pfizer Vaccines,
Sanofi Pasteur, Sanofi Pasteur MSD, Takeda, and Vaxeal.
EBE represents major innovative biotech companies operating in Europe. Representative companies
within EBE, and involved in the field of immuno-therapies are: Amgen, AstraZeneca, Baxter, Bayer,
Merck, Roche and Sanofi amongst others.
Vaccines Europe
An industry for healthy lives
Public-Private partnership is at the heart of Vaxeal’s product development strategy. Vaxeal plays a key bridging role in leading
basic scientific discoveries emanating from academic research through clinical proof-of-concept.
Partners
7. Management
Team
Dr Ahmed Bouzidi, PhD, MBA – CEO
• Successful entrepreneur in Europe and China
• Founder & CEO of SEDAC (FR, US, China)
• Founder and CEO of Biophysiomics (Lux, China)
• Board Member of Vaccines Europe
• Board Member of EBE-Biopharma
Serge Grisard, MBA – EVP Corporate Development
• 20 years experience in healthcare product development,
commercialization and PPPs
• Global management at Siemens Medical, Pfizer, Astra-Zeneca, and a
range of start-ups
Pr Giampietro Corradin, PhD – CTO
• 30 years of experience in vaccine development
• Worldwide expert in LSP-based vaccines
• Development of several vaccine candidates
Dr Jérôme Kerzerho, PhD – Director R&D
• Expert in immunology
• Discovered the tumor antigens Midkine
• Identified new clinically relevant T cell epitopes in Survivin and
Midkine tumor antigens
• Previously head of a multidisciplinary team working on
pathogenesis of HIV and HCV disease
John Samuelson - CFO
• 20 years in global capital markets
• Early-stage private equity investments
• Project management in Russia, Middle East and Europe
• Advisor to UHNW clients
Vaxeal’s highly experienced executive team has an extensive track record in
vaccine development and regulatory compliance. The Board also brings a
wealth of diverse corporate and M&A experience.
8. Headquarters
Vaxeal
Holding
SA
Avenue
Paul
Cérésole
24
1800
Vevey
–
Switzerland
Phone:
+41
21
977
3000
Fax:
+41
21
922
1000
International Offices
Vaxeal Research SAS
Genopoles Entreprises
4 Rue Pierre Fontaine
91058 Evry Cedex - France
Phone: +33 1 60 87 89 31
Fax: +33 1 60 87 89 99
Vaxeal IP Management Sàrl
Avenue de Tivoli 3
1700 Fribourg – Switzerland
Vaxeal China Inc.
bioBay, 218 Xing Hu Road,
A2 Building, Suite 214,
Suzhou Industrial Park,
Suzhou 215125 – China
For further information regarding Vaxeal products and solutions, please contact us at: info@vaxeal.net
